Global Microbubble Contrast Media Market – Industry Trends and Forecast to 2029

Global Microbubble Contrast Media Market, By Therapeutic Area (Cardiovascular Diseases, Renal and Associated Diseases, Others), Application (Molecular Imaging, Gene Therapy, Drug Delivery, Stem Cells Delivery), Route of Administration (Rectal, Oral, Injectable), Form (Tablet, Powder, Liquid, Paste), Procedures (X-ray/Computed Tomography (CT), Magnetic Resonance Imaging (MRI)) – Industry Trends and Forecast to 2029.

 Microbubble Contrast Media Market Analysis and Size

The use of microbubble contrast agents in ultrasound imaging for general tissue delineation and perfusion is gaining popularity. Microbubbles, as contrast materials, have a low dosage requirement and excellent detection sensitivity. Targeting ligands on the surface of microbubbles allow for the selective accumulation of these particles in areas of interest that have an increased level of receptor molecules on vascular endothelium. These goods aid in determining the need of preoperative scans before the operations and therapy in interventional procedures, which is expected to help the market growth of microbubble contrast media.

Data Bridge Market Research analyses that the microbubble contrast media market which is expected to at a healthy CAGR during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Microbubble Contrast Media Market Scope and Segmentation  

Market Definition

Contrast media, also known as contrast agents, is a substance that is usually transparent to X-rays and is used in medical imaging to speed up the contrast of fluids or structures. Microbubbles are used as a blood pool agent for contrast ultrasound imaging in cardiology and radiology. They are widely used in gene therapy, stem cell delivery, drug delivery, molecular imaging, and other applications. Microbubbles can also be used in conjunction with ligand molecules that target molecular markers of disease. The main purpose of microbubble-based ultrasound contrast agents is to monitor the biomarker condition of vascular endothelium, image inflammation, and visualise tumour vasculature, among other things.

Global Microbubble Contrast Media Market Dynamics

Drivers

• Increasing image-guided surgeries

Image-guided surgeries (IGS) are gaining popularity. These procedures can be used to diagnose and treat a variety of conditions. The growing need and demand for imaging refinement during surgeries necessitates novel methods of data acquisition, processing, and display, as well as a thorough understanding of the imaging process and its applications in therapy. This need is very well served by image-guided procedures, which has resulted in increased demand for image-guided procedures for diagnostics and treatment, and thus has served as a market growth factor.

• Increasing prevalence of complex comorbidities

The increasing prevalence of complex comorbidities and chronic diseases has increased diagnostic imaging tests such as ultrasound, X-rays, and advanced imaging technology such as MRI and CT scans. For instance, GE Healthcare received FDA approval for Clariscan, a contrast agent used in macrocyclic MRI in November 2019. These products aid in the identification of the need for perioperative scans prior to surgeries and treatment in interventional procedures, which is expected to drive market growth.

Opportunities

• Rise in the prevalence of chronic conditions

The occurrence of chronic conditions with multiple comorbidities is higher in elder people. According to the National Council on Aging, nearly 80% of people aged 65 and older have at least one chronic condition, with nearly 70% of Medicare beneficiaries having more than two chronic conditions, and nearly 77.0 million people in the United States are expected to be 65 and older by 2034.

Furthermore, according to an American Heart Association report, the incidence of heart failure is increasing in the United States, and it is one of the leading causes of death in the country. In the United States in 2020, approximately 659,000 people died as a result of cardiovascular diseases. The number of people with heart disease is expected to rise by 46% by 2030.

• Launch of new products

The launch of digital tools to help with contrast agent injection management is projected to fuel market expansion. For instance, in 2018, Guerbet introduced Contrast&Care 2.0, a digital system that links all CT, Cath lab, and MRI injectors and has smart reader & connectivity features, allowing users to scan and read data on both their smartphones and laptops.

Restraints/Challenges

• High cost of microbubble contrast media

High cost of microbubble contrast media and the low adoption rate in emerging and underdeveloped countries will obstruct the market's growth rate. Imaging the kidney with microbubble contrast agents because of the poor contrast of B-mode imaging for parenchymal disease and the limited sensitivity of colour doppler for the detection of intracortical capillaries and deep pedicular vessels.

This microbubble contrast media market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the microbubble contrast media market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Microbubble Contrast Media Market

The COVID-19 epidemic negatively impacted the microbubble contrast media market, resulting in a drop in patient visits to hospitals. The introduction of accurate and efficient digital methods for managing contrast agent injection is predicted to drive market expansion. Numerous research has shown that COVID has a devastating impact on health, including heart attacks and strokes, this may drive future market expansion. The pandemic has put tremendous strain on the healthcare systems. To conserve healthcare resources for COVID-19 patients and stem the spread of the disease, healthcare institutions and providers were directed to stop performing medical examinations and elective surgical procedures. As a result the patients concentrating on COVID-19 in the early months of the pandemic, the diagnosis of cardiac diseases decreased by nearly two-thirds globally. Similar declines in colon, breast, prostate, and lung screenings—75%, 85%, 75%, 74%, and 56%, respectively—show a decline in revenue for 2020.

Recent developments

• In February 2022, Lopamidal by Beijing Beilu Pharmaceuticals passed the generic drug Consistency Evaluation. The evaluation aids in comparing the quality and efficacy of generic drugs to the brand version of the drug.
• In July 2020, Bayer and Siemens Healthineers presented a new Imaging System Interface (ISI) for magnetic resonance imaging. The Interface combines the Bayer MRXperion MR Injection System and the Siemens Healthineers MR scanner to overcome the limitations of the traditional method.

Global Microbubble Contrast Media Market Scope

The microbubble contrast media market is segmented on the basis of therapeutic area, application, route of administration, form and procedures. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapeutic Area

• Cardiovascular Diseases
• Renal and Associated Diseases
• Others

 Application

• Molecular Imaging
• Gene Therapy
• Drug Delivery
• Stem Cells Delivery

 Route of Administration

• Rectal
• Oral
• Injectable

 Form

• Tablet
• Powder
• Liquid
• Paste

 Procedures

• X-ray/Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)

Microbubble Contrast Media Market Regional Analysis/Insights

The microbubble contrast media market is analyzed and market size insights and trends are provided by country, therapeutic area, application, route of administration, form and procedures as referenced above.

The countries covered in the microbubble contrast media market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the microbubble contrast media market due to an increase in the availability of advanced technologies, the presence of well-established healthcare facilities, and the demand for diagnostic procedures in this region. 

Asia-Pacific is expected to dominate at the highest growth rate in the forecast period of 2022 to 2029 due to the rise in the research and development investment in the contrast agents in this region and the prevalence of chronic disease.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Microbubble Contrast Media Market Share Analysis

The microbubble contrast media market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to microbubble contrast media market.

Some of the major players operating in the microbubble contrast media market are:

• Lantheus (U.S.)
• Bracco Imaging S.p.A. (Italy)
• General Electric (U.S.)
• DAIICHI SANKYO COMPANY, LIMITED (Japan)
• nanoPET Pharma GmbH (Germany)
• Trust Bio-sonics (Taiwan)
• FUJIFILM VisualSonics Inc. (Canada)
• Trivitron Healthcare (India)
• Siemens (Germany)